$NOVO B (-0,19%) and the battle for the 200-day line!
The Novo Nordisk share is currently stuck at the 200-day line after its strong rally from its low of 266.90 Danish kroner at the end of November. Recently, some analysts have also been rather cautious, which means that momentum is currently lacking. Meanwhile, investors should keep an eye on an important date.
Several analyst firms remain cautiously positioned on Novo Nordisk ahead of the fourth quarter figures, which are to be presented on February 4. UBS is sticking to its neutral assessment and sees the fair value of the share at 390 Danish kroner. The group's outlook for 2026 is expected to be rather defensive. The analysts believe that the oral version of the weight loss drug Wegovy will remain decisive, particularly with regard to its earning power.
Barclays also remains cautious and continues to rate the share at "Equal Weight". The target price is 360 crowns. Initial market signals following the start of sales of the tablet form of Wegovy at the beginning of January are highlighted as encouraging.
Jefferies is much more skeptical. The analyst firm confirms its sell recommendation with a target price of 270 crowns. In the short term, weekly sales data from Wegovy in particular will influence the share price. However, despite high demand at the beginning of the year, the analysts do not expect any noticeable positive effects on business development - neither in 2025 nor in 2026.
I feel very comfortable with my short. As long as we don't close above 400DKK, everything is in the green.
